0.8537

2.62% -0.0164

Cytomx Therapeutics Inc (CTMX)

Overview News Price History Option Chain Financials Discussions Forecast

Cytomx Therapeutics Inc stock is traded at $0.8537, with a volume of 97,343. It is down -2.62% in the last 24 hours and down -26.96% over the past month. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Previous Close:

$0.8701

Open:

$0.87

24h Volume:

97,343

Relative Volume:

0.12

Market Cap:

$68.44M

Revenue:

$101.21M

Net Income/Loss:

$-569.00K

P/E Ratio:

-1.0163

EPS:

-0.84

Net Cash Flow:

$-56.88M

1W Performance:

-15.27%

1M Performance:

-26.96%

6M Performance:

-54.69%

1Y Performance:

-35.07%

1-Day Range:

$0.843

$0.87

1-Week Range:

$0.833

$1.0131

52-Week Range:

$0.833

$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name

Cytomx Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

650.515.3185

Address

151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA

Employee

122

Twitter

@cytomxinc

Next Earnings Date

2024-11-07

Latest SEC Filings

CTMX's Discussions on Twitter

Compare CTMX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTMX	0.8537	68.44M	101.21M	-569.00K	-56.88M	-0.84
VRTX	447.51	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.90	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.12	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.75	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.52	24.49B	3.30B	-501.07M	1.03B	11.54

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight
May-09-24	Upgrade	Wedbush	Neutral → Outperform
May-06-24	Upgrade	Jefferies	Hold → Buy
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-07-22	Downgrade	Jefferies	Buy → Hold
Jul-07-22	Downgrade	Mizuho	Buy → Neutral
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Jan-18-22	Upgrade	Barclays	Underweight → Overweight
Nov-15-21	Initiated	BTIG Research	Buy
May-28-21	Downgrade	Barclays	Equal Weight → Underweight
Mar-29-21	Initiated	JP Morgan	Overweight
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold
May-14-20	Reiterated	H.C. Wainwright	Buy
Mar-24-20	Upgrade	Wedbush	Neutral → Outperform
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-20-19	Initiated	Guggenheim	Buy
Nov-11-19	Downgrade	Wedbush	Outperform → Neutral
Jun-13-19	Initiated	Mizuho	Buy
May-14-19	Initiated	Cantor Fitzgerald	Overweight
Mar-11-19	Initiated	Barclays	Overweight
Nov-26-18	Initiated	Piper Jaffray	Overweight
Oct-15-18	Initiated	Goldman	Neutral
Sep-13-18	Initiated	H.C. Wainwright	Buy
Jun-01-18	Initiated	SunTrust	Buy
Jan-05-18	Initiated	Citigroup	Buy
Sep-08-17	Initiated	Wedbush	Outperform
Mar-27-17	Initiated	H.C. Wainwright	Buy
Mar-02-17	Initiated	Instinet	Buy
Jan-03-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-02-15	Initiated	Oppenheimer	Outperform

View All

Cytomx Therapeutics Inc Stock (CTMX) Latest News

Nov 19, 2024

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada

Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024

Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024

Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024

Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024

Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024